Business · 28/06/2022
FDA Announces Final Guidance for Developing Drugs and Biologics for Renal Cell Carcinoma Adjuvant Treatment
The FDA has released a final guidance document to help pharmaceutical companies develop effective treatments for renal cell carcinoma, a type of kidney cancer, and provides recommendations for sponsors on the development process.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →